Annals of Oncology Advance Access published online on September 9, 2007
Annals of Oncology, doi:10.1093/annonc/mdm272
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
review |
Management of venous port systems in oncology: a review of current evidence
,*
1 German Breast Group, Neu Isenburg
2 Frauenklinik rechts der Isar, Technische Universität München
3 Frauenklinik, Universitätsklinikum Frankfurt am Main, Germany
* Correspondence to: Dr A. K. Baumgärtner, Frauenklinik rechts der Isar der Technische Universität München, Ismaninger Str. 22, 81675 München, Germany. Tel: +49-(0)894140-6658; Fax: +49-(0)894140-4846; E-mail: annebaumgaertner{at}web.de
Background: Over the last decades, many changes have occurred in oncology with new chemotherapy combinations and more complex application schemes becoming available. Central venous catheters and implantable venous port systems have become widely used and have facilitated the problem of vascular access. However, important complications are associated with permanent central venous catheters.
Material and methods: This review summarizes evidence on venous port system use published in Medline up to February 2007. Moreover, recent guidelines for the prevention and management of catheter-related infections issued by the Infectious Diseases Society of America, the American College of Critical Care Medicine, the Society for Healthcare Epidemiology of America, the Center for Disease Control and Prevention, Atlanta, and the Infectious Diseases Working Party of the German Society of Hematology and Oncology are included.
Results: Sterile precautions are essential when implanting and accessing port systems. Infections must be treated with adequate antimicrobial therapy. Catheter-related thromboembolic complications were found at a rate of 12–64% in retrospective studies. Five current clinical trials investigated the effect of prophylactic anticoagulation with either low molecular weight heparin or warfarin in cancer patients with central venous devices. On the basis of these results, routine anticoagulation cannot be recommended.
Conclusions: This article reviews the current literature on long-term complications of venous port systems, focusing on infection and thrombosis. In addition, it summarizes the evidence regarding routine maintenance of port systems in follow-up care.
central venous catheter, chemotherapy, infection, thrombosis, venous port system
Both authors contributed equally to this manuscript. Received for publication March 17, 2007. Accepted for publication April 30, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Debourdeau, D. Kassab Chahmi, G. Le Gal, I. Kriegel, E. Desruennes, M.-C. Douard, I. Elalamy, G. Meyer, P. Mismetti, M. Pavic, et al. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group Ann. Onc., September 1, 2009; 20(9): 1459 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Biffi, F. Orsi, S. Pozzi, U. Pace, G. Bonomo, L. Monfardini, P. Della Vigna, N. Rotmensz, D. Radice, M. G. Zampino, et al. Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial Ann. Onc., May 1, 2009; 20(5): 935 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Oz, R. Demirhan, B. Onan, and I. Sancakli Pulmonary Artery Pseudoaneurysm After a Vascular Access Port Catheter Implantation Ann. Thorac. Surg., January 1, 2009; 87(1): 295 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gallieni, M. Pittiruti, and R. Biffi Vascular Access in Oncology Patients CA Cancer J Clin, November 1, 2008; 58(6): 323 - 346. [Abstract] [Full Text] [PDF]
|
|
E-letters:
Read all E-letters
- Management of venous port systems in oncology: - practical aspect
- Igor Olejnik, et al.
- Annals of Oncology, 16 Jul 2008 [Full text]